# The Effectiveness of Topical Keratolytics (Alpha Hydroxy Acids/Beta Hydroxy Acids/Urea) in Treating Keratosis Pilaris: A Review of the Literature

**Authors:** Eleftheria Dampa

PMC · DOI: 10.7759/cureus.100507 · 2025-12-31

## TL;DR

This paper reviews how well topical keratolytics like AHAs, BHAs, and urea work for treating keratosis pilaris, a common skin condition causing rough bumps.

## Contribution

The paper provides a comprehensive review of the effectiveness of topical keratolytics in treating keratosis pilaris, highlighting gaps in current evidence.

## Key findings

- Topical keratolytics (AHAs, BHAs, urea) may improve keratosis pilaris by reducing corneocyte cohesion and improving skin hydration.
- Evidence is limited by small studies, inconsistent outcomes, and lack of long-term data.
- KP is often linked to skin barrier dysfunction and conditions like atopic dermatitis.

## Abstract

Keratosis pilaris (KP) is a highly prevalent, benign disorder of follicular keratinization characterized by rough keratotic papules and variable perifollicular erythema, most commonly affecting the extensor upper arms, thighs, and buttocks. Although medically harmless, KP is frequently associated with cosmetic distress, reduced self-confidence, and persistent dissatisfaction with skin texture and appearance. The fundamental pathological process involves follicular hyperkeratosis with retention keratosis and abnormal desquamation, often occurring in the context of xerosis and epidermal barrier dysfunction, including associations with atopic dermatitis, ichthyosis vulgaris, and filaggrin-related barrier impairment. These mechanisms provide a strong rationale for topical keratolytic therapy, which aims to reduce corneocyte cohesion, facilitate desquamation, soften keratin plugs, and improve hydration of the stratum corneum. Topical keratolytics remain reasonable first-line, symptom-directed options for KP, with AHAs, BHAs, and urea all demonstrating potential benefit. However, the overall evidence base is constrained by small sample sizes, heterogeneous outcome measures, limited blinding, and short follow-up, with sparse long-term maintenance data and limited differentiation between texture-dominant and erythematous KP phenotypes.

## Linked entities

- **Chemicals:** Alpha Hydroxy Acids (PubChem CID 23668197), urea (PubChem CID 1176)
- **Diseases:** Keratosis Pilaris (MONDO:0018855), atopic dermatitis (MONDO:0004980), ichthyosis vulgaris (MONDO:0024304)

## Full-text entities

- **Genes:** FLG (filaggrin) [NCBI Gene 2312] {aka ATOD2, FLG-1, FLG1}
- **Diseases:** KP (MESH:C537412), atopic dermatitis (MESH:D003876), retention keratosis (MESH:D016055), follicular hyperkeratosis (MESH:D005497), erythema (MESH:D004890), ichthyosis vulgaris (MESH:D016112)
- **Chemicals:** Urea (MESH:D014508), Alpha Hydroxy Acids (-), BHAs (MESH:D002083)

---
Source: https://tomesphere.com/paper/PMC12860576